Research programme: central nervous system therapeutics - Astellas Pharma/Icagen
Latest Information Update: 24 Feb 2009
Price :
$50 *
At a glance
- Originator Icagen
- Developer Astellas Pharma; Icagen
- Class Small molecules
- Mechanism of Action Potassium channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Attention-deficit hyperactivity disorder; Dementia; Memory disorders
Most Recent Events
- 06 Nov 2008 Discontinued - Preclinical for Attention-deficit hyperactivity disorder in USA (unspecified route)
- 06 Nov 2008 Discontinued - Preclinical for Dementia in Japan (unspecified route)
- 06 Nov 2008 Discontinued - Preclinical for Memory disorders in Japan (unspecified route)